Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is extremely pleased to announce that the US Patent and Trademark Office (USPTO) has indicated it is issuing an allowance for the granting of a patent for ALA-002, the company’s lead investigational MDXX Novel Chemical Entity (NCE). This provides the Company a strong basis for ongoing protection of this intellectual property (IP).
Related news for (MDXXF)
- PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
- PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
- PharmAla Closes Private Placement and Concurrent Debt Settlement
- PharmAla Announces Private Placement and Concurrent Debt Settlement